Titre : Antienzymes

Antienzymes : Questions médicales fréquentes

Nom anglais: Enzyme Inhibitors

Descriptor UI: D004791

Tree Number: D27.505.519.389

Termes MeSH sélectionnés :

Peritoneum

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une inhibition enzymatique ?

Des tests sanguins et des analyses biochimiques évaluent l'activité enzymatique.
Inhibiteurs enzymatiques Tests de laboratoire
#2

Quels symptômes indiquent une inhibition enzymatique ?

Des symptômes comme la fatigue, la douleur abdominale ou des troubles digestifs peuvent apparaître.
Symptômes Troubles digestifs
#3

Quels tests sont utilisés pour détecter les antienzymes ?

Les tests d'activité enzymatique et les dosages spécifiques d'anticorps sont courants.
Tests diagnostiques Anticorps
#4

Peut-on utiliser l'imagerie pour diagnostiquer ?

L'imagerie peut aider à évaluer les organes affectés, mais n'est pas spécifique aux antienzymes.
Imagerie médicale Évaluation des organes
#5

Quels marqueurs biochimiques sont associés aux antienzymes ?

Les niveaux d'enzymes spécifiques dans le sang peuvent indiquer une inhibition enzymatique.
Marqueurs biochimiques Enzymes

Symptômes 5

#1

Quels sont les symptômes d'une inhibition enzymatique ?

Les symptômes incluent douleurs abdominales, nausées, et troubles métaboliques.
Symptômes Troubles métaboliques
#2

L'inhibition enzymatique peut-elle causer des douleurs ?

Oui, elle peut entraîner des douleurs dues à des troubles digestifs ou métaboliques.
Douleur Troubles digestifs
#3

Y a-t-il des symptômes spécifiques selon l'enzyme inhibée ?

Oui, les symptômes varient selon l'enzyme affectée, comme la lactase ou la lipase.
Enzymes Symptômes spécifiques
#4

Les symptômes sont-ils toujours présents ?

Non, certains patients peuvent être asymptomatiques malgré une inhibition enzymatique.
Asymptomatique Inhibition enzymatique
#5

Comment les symptômes évoluent-ils avec le temps ?

Les symptômes peuvent s'aggraver si l'inhibition persiste sans traitement approprié.
Évolution des symptômes Traitement

Prévention 5

#1

Comment prévenir l'inhibition enzymatique ?

Une alimentation équilibrée et l'évitement de substances toxiques peuvent aider.
Prévention Alimentation équilibrée
#2

Les vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?

Certaines vaccinations peuvent prévenir des infections qui causent des inhibitions enzymatiques.
Vaccination Infections
#3

Y a-t-il des habitudes de vie à adopter ?

Oui, éviter l'alcool et le tabac peut réduire le risque d'inhibition enzymatique.
Habitudes de vie Alcool
#4

Les contrôles médicaux réguliers sont-ils importants ?

Oui, des contrôles réguliers permettent de détecter précocement des problèmes enzymatiques.
Contrôles médicaux Détection précoce
#5

L'éducation sur les médicaments est-elle nécessaire ?

Oui, comprendre les effets des médicaments aide à prévenir les inhibitions enzymatiques.
Éducation médicale Médicaments

Traitements 5

#1

Quels traitements existent pour l'inhibition enzymatique ?

Les traitements incluent des médicaments spécifiques et des modifications diététiques.
Traitements Médicaments
#2

Les antienzymes sont-ils utilisés en chimiothérapie ?

Oui, certains antienzymes sont utilisés pour cibler des enzymes dans les cellules cancéreuses.
Chimiothérapie Anticancéreux
#3

Comment les inhibiteurs enzymatiques sont-ils administrés ?

Ils peuvent être administrés par voie orale, intraveineuse ou topique selon le cas.
Administration de médicaments Voies d'administration
#4

Y a-t-il des effets secondaires aux antienzymes ?

Oui, des effets secondaires comme des nausées, des éruptions cutanées ou des douleurs peuvent survenir.
Effets secondaires Nausées
#5

Les traitements sont-ils personnalisés ?

Oui, le traitement est souvent adapté en fonction de la cause et de la gravité de l'inhibition.
Médecine personnalisée Inhibition enzymatique

Complications 5

#1

Quelles complications peuvent survenir avec l'inhibition enzymatique ?

Des complications comme des troubles métaboliques ou des maladies organiques peuvent survenir.
Complications Troubles métaboliques
#2

L'inhibition enzymatique peut-elle entraîner des maladies chroniques ?

Oui, une inhibition prolongée peut contribuer à des maladies chroniques comme le diabète.
Maladies chroniques Diabète
#3

Y a-t-il des risques de surdosage avec les antienzymes ?

Oui, un surdosage peut entraîner des effets indésirables graves et des complications.
Surdosage Effets indésirables
#4

Comment gérer les complications liées aux antienzymes ?

La gestion implique un suivi médical régulier et des ajustements de traitement.
Gestion des complications Suivi médical
#5

Les complications sont-elles réversibles ?

Certaines complications peuvent être réversibles avec un traitement approprié et rapide.
Réversibilité Traitement

Facteurs de risque 5

#1

Quels sont les facteurs de risque d'inhibition enzymatique ?

Les facteurs incluent des antécédents familiaux, des maladies héréditaires et des habitudes alimentaires.
Facteurs de risque Antécédents familiaux
#2

L'âge influence-t-il le risque d'inhibition enzymatique ?

Oui, le risque augmente souvent avec l'âge en raison de la dégradation enzymatique naturelle.
Âge Dégradation enzymatique
#3

Les maladies auto-immunes sont-elles un facteur de risque ?

Oui, certaines maladies auto-immunes peuvent augmenter le risque d'inhibition enzymatique.
Maladies auto-immunes Inhibition enzymatique
#4

Le mode de vie affecte-t-il le risque ?

Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque.
Mode de vie Alimentation
#5

Les médicaments peuvent-ils être des facteurs de risque ?

Oui, certains médicaments peuvent interférer avec l'activité enzymatique et augmenter le risque.
Médicaments Interférence enzymatique
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Antienzymes : Questions médicales les plus fréquentes", "headline": "Antienzymes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Antienzymes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-26", "dateModified": "2025-04-22", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Antienzymes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Mécanismes moléculaires de l'action pharmacologique", "url": "https://questionsmedicales.fr/mesh/D045504", "about": { "@type": "MedicalCondition", "name": "Mécanismes moléculaires de l'action pharmacologique", "code": { "@type": "MedicalCode", "code": "D045504", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase", "alternateName": "5-Lipoxygenase-Activating Protein Inhibitors", "url": "https://questionsmedicales.fr/mesh/D058946", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase", "code": { "@type": "MedicalCode", "code": "D058946", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.086" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de l'acétaldéhyde déshydrogénase", "alternateName": "Acetaldehyde Dehydrogenase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065086", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de l'acétaldéhyde déshydrogénase", "code": { "@type": "MedicalCode", "code": "D065086", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.089" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de l'adénosine désaminase", "alternateName": "Adenosine Deaminase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D058892", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de l'adénosine désaminase", "code": { "@type": "MedicalCode", "code": "D058892", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.092" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs des adénylate cyclases", "alternateName": "Adenylyl Cyclase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000067956", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des adénylate cyclases", "code": { "@type": "MedicalCode", "code": "D000067956", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.108" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la calcineurine", "alternateName": "Calcineurin Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065095", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la calcineurine", "code": { "@type": "MedicalCode", "code": "D065095", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.174" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de l'anhydrase carbonique", "alternateName": "Carbonic Anhydrase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D002257", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de l'anhydrase carbonique", "code": { "@type": "MedicalCode", "code": "D002257", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.200" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs et modulateurs de la gamma-secrétase", "alternateName": "Gamma Secretase Inhibitors and Modulators", "url": "https://questionsmedicales.fr/mesh/D000091062", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs et modulateurs de la gamma-secrétase", "code": { "@type": "MedicalCode", "code": "D000091062", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.315" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs des enzymes du cytochrome P-450", "alternateName": "Cytochrome P-450 Enzyme Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065607", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des enzymes du cytochrome P-450", "code": { "@type": "MedicalCode", "code": "D065607", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs du cytochrome P-450 CYP1A2", "alternateName": "Cytochrome P-450 CYP1A2 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065609", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cytochrome P-450 CYP1A2", "code": { "@type": "MedicalCode", "code": "D065609", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335.120" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cytochrome P-450 CYP2B6", "alternateName": "Cytochrome P-450 CYP2B6 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065686", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cytochrome P-450 CYP2B6", "code": { "@type": "MedicalCode", "code": "D065686", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335.260" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cytochrome P-450 CYP2C8", "alternateName": "Cytochrome P-450 CYP2C8 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065687", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cytochrome P-450 CYP2C8", "code": { "@type": "MedicalCode", "code": "D065687", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335.308" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cytochrome P-450 CYP2C19", "alternateName": "Cytochrome P-450 CYP2C19 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065689", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cytochrome P-450 CYP2C19", "code": { "@type": "MedicalCode", "code": "D065689", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335.319" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cytochrome P-450 CYP2C9", "alternateName": "Cytochrome P-450 CYP2C9 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065688", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cytochrome P-450 CYP2C9", "code": { "@type": "MedicalCode", "code": "D065688", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335.329" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cytochrome P-450 CYP2D6", "alternateName": "Cytochrome P-450 CYP2D6 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065690", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cytochrome P-450 CYP2D6", "code": { "@type": "MedicalCode", "code": "D065690", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335.368" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cytochrome P-450 CYP2E1", "alternateName": "Cytochrome P-450 CYP2E1 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065691", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cytochrome P-450 CYP2E1", "code": { "@type": "MedicalCode", "code": "D065691", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335.421" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cytochrome P-450 CYP3A", "alternateName": "Cytochrome P-450 CYP3A Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065692", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cytochrome P-450 CYP3A", "code": { "@type": "MedicalCode", "code": "D065692", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.335.503" } } } ] }, { "@type": "MedicalWebPage", "name": "Antifoliques", "alternateName": "Folic Acid Antagonists", "url": "https://questionsmedicales.fr/mesh/D005493", "about": { "@type": "MedicalCondition", "name": "Antifoliques", "code": { "@type": "MedicalCode", "code": "D005493", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.350" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de désacétylase d'histone", "alternateName": "Histone Deacetylase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D056572", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de désacétylase d'histone", "code": { "@type": "MedicalCode", "code": "D056572", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.360" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de l'intégrase", "alternateName": "Integrase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D019429", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de l'intégrase", "code": { "@type": "MedicalCode", "code": "D019429", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.375" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la lipoxygénase", "alternateName": "Lipoxygenase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D016859", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la lipoxygénase", "code": { "@type": "MedicalCode", "code": "D016859", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.480" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la monoamine oxydase", "alternateName": "Monoamine Oxidase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D008996", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la monoamine oxydase", "code": { "@type": "MedicalCode", "code": "D008996", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.616" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la synthèse d'acide nucléique", "alternateName": "Nucleic Acid Synthesis Inhibitors", "url": "https://questionsmedicales.fr/mesh/D019384", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la synthèse d'acide nucléique", "code": { "@type": "MedicalCode", "code": "D019384", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.675" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de l'ornithine décarboxylase", "alternateName": "Ornithine Decarboxylase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065108", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de l'ornithine décarboxylase", "code": { "@type": "MedicalCode", "code": "D065108", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.705" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la phosphodiestérase", "alternateName": "Phosphodiesterase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D010726", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la phosphodiestérase", "code": { "@type": "MedicalCode", "code": "D010726", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.735" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs de la phosphodiestérase-3", "alternateName": "Phosphodiesterase 3 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D058987", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la phosphodiestérase-3", "code": { "@type": "MedicalCode", "code": "D058987", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.735.249" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la phosphodiestérase-4", "alternateName": "Phosphodiesterase 4 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D058988", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la phosphodiestérase-4", "code": { "@type": "MedicalCode", "code": "D058988", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.735.374" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la phosphodiestérase-5", "alternateName": "Phosphodiesterase 5 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D058986", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la phosphodiestérase-5", "code": { "@type": "MedicalCode", "code": "D058986", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.735.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Inhibiteurs des phosphoinositide-3 kinases", "alternateName": "Phosphoinositide-3 Kinase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000081082", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des phosphoinositide-3 kinases", "code": { "@type": "MedicalCode", "code": "D000081082", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.736" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la phospholipase A2", "alternateName": "Phospholipase A2 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D064801", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la phospholipase A2", "code": { "@type": "MedicalCode", "code": "D064801", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.737" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de prolyle hydroxylases", "alternateName": "Prolyl-Hydroxylase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D064800", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de prolyle hydroxylases", "code": { "@type": "MedicalCode", "code": "D064800", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.740" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de protéases", "alternateName": "Protease Inhibitors", "url": "https://questionsmedicales.fr/mesh/D011480", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de protéases", "code": { "@type": "MedicalCode", "code": "D011480", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine", "alternateName": "Angiotensin-Converting Enzyme Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000806", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine", "code": { "@type": "MedicalCode", "code": "D000806", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.085" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs des vasopeptidases", "alternateName": "Vasopeptidase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000075563", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des vasopeptidases", "code": { "@type": "MedicalCode", "code": "D000075563", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.085.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Inhibiteurs des vasopeptidases", "alternateName": "Vasopeptidase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000075563", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des vasopeptidases", "code": { "@type": "MedicalCode", "code": "D000075563", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.085.500" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la cystéine protéinase", "alternateName": "Cysteine Proteinase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D015853", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la cystéine protéinase", "code": { "@type": "MedicalCode", "code": "D015853", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.325" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs des caspases", "alternateName": "Caspase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D061945", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des caspases", "code": { "@type": "MedicalCode", "code": "D061945", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.325.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Inhibiteurs des caspases", "alternateName": "Caspase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D061945", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des caspases", "code": { "@type": "MedicalCode", "code": "D061945", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.325.500" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de métalloprotéinases matricielles", "alternateName": "Matrix Metalloproteinase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D061965", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de métalloprotéinases matricielles", "code": { "@type": "MedicalCode", "code": "D061965", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.610" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du protéasome", "alternateName": "Proteasome Inhibitors", "url": "https://questionsmedicales.fr/mesh/D061988", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du protéasome", "code": { "@type": "MedicalCode", "code": "D061988", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.705" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la rénine", "alternateName": "Renin Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000092502", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la rénine", "code": { "@type": "MedicalCode", "code": "D000092502", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.753" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la sérine protéinase", "alternateName": "Serine Proteinase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D015842", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la sérine protéinase", "code": { "@type": "MedicalCode", "code": "D015842", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.800" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs de serine peptidase de type Kazal", "alternateName": "Serine Peptidase Inhibitors, Kazal Type", "url": "https://questionsmedicales.fr/mesh/D000074162", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de serine peptidase de type Kazal", "code": { "@type": "MedicalCode", "code": "D000074162", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.800.562" } } }, { "@type": "MedicalWebPage", "name": "Serpines", "alternateName": "Serpins", "url": "https://questionsmedicales.fr/mesh/D015843", "about": { "@type": "MedicalCondition", "name": "Serpines", "code": { "@type": "MedicalCode", "code": "D015843", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.800.675" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs trypsiques", "alternateName": "Trypsin Inhibitors", "url": "https://questionsmedicales.fr/mesh/D014361", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs trypsiques", "code": { "@type": "MedicalCode", "code": "D014361", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.800.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de serine peptidase de type Kazal", "alternateName": "Serine Peptidase Inhibitors, Kazal Type", "url": "https://questionsmedicales.fr/mesh/D000074162", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de serine peptidase de type Kazal", "code": { "@type": "MedicalCode", "code": "D000074162", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.800.562" } } }, { "@type": "MedicalWebPage", "name": "Serpines", "alternateName": "Serpins", "url": "https://questionsmedicales.fr/mesh/D015843", "about": { "@type": "MedicalCondition", "name": "Serpines", "code": { "@type": "MedicalCode", "code": "D015843", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.800.675" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs trypsiques", "alternateName": "Trypsin Inhibitors", "url": "https://questionsmedicales.fr/mesh/D014361", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs trypsiques", "code": { "@type": "MedicalCode", "code": "D014361", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.745.800.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de protéines kinases", "alternateName": "Protein Kinase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D047428", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de protéines kinases", "code": { "@type": "MedicalCode", "code": "D047428", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.755" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs des Janus kinases", "alternateName": "Janus Kinase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000075242", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des Janus kinases", "code": { "@type": "MedicalCode", "code": "D000075242", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.755.500" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de protéine-tyrosine kinase", "alternateName": "Tyrosine Protein Kinase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000092004", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de protéine-tyrosine kinase", "code": { "@type": "MedicalCode", "code": "D000092004", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.755.875" } } } ] }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la synthèse protéique", "alternateName": "Protein Synthesis Inhibitors", "url": "https://questionsmedicales.fr/mesh/D011500", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la synthèse protéique", "code": { "@type": "MedicalCode", "code": "D011500", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.760" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la pompe à protons", "alternateName": "Proton Pump Inhibitors", "url": "https://questionsmedicales.fr/mesh/D054328", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la pompe à protons", "code": { "@type": "MedicalCode", "code": "D054328", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.848" } } }, { "@type": "MedicalWebPage", "name": "Agents découplants", "alternateName": "Uncoupling Agents", "url": "https://questionsmedicales.fr/mesh/D014475", "about": { "@type": "MedicalCondition", "name": "Agents découplants", "code": { "@type": "MedicalCode", "code": "D014475", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389.936" } } } ], "about": { "@type": "MedicalCondition", "name": "Antienzymes", "alternateName": "Enzyme Inhibitors", "code": { "@type": "MedicalCode", "code": "D004791", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Xiaoxi Liu", "url": "https://questionsmedicales.fr/author/Xiaoxi%20Liu", "affiliation": { "@type": "Organization", "name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA." } }, { "@type": "Person", "name": "Robert S Magin", "url": "https://questionsmedicales.fr/author/Robert%20S%20Magin", "affiliation": { "@type": "Organization", "name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA." } }, { "@type": "Person", "name": "Nathan J Schauer", "url": "https://questionsmedicales.fr/author/Nathan%20J%20Schauer", "affiliation": { "@type": "Organization", "name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA." } }, { "@type": "Person", "name": "Sara J Buhrlage", "url": "https://questionsmedicales.fr/author/Sara%20J%20Buhrlage", "affiliation": { "@type": "Organization", "name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu." } }, { "@type": "Person", "name": "R Gentry Wilkerson", "url": "https://questionsmedicales.fr/author/R%20Gentry%20Wilkerson", "affiliation": { "@type": "Organization", "name": "Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: gwilkerson@som.umaryland.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "T cells in the peritoneum.", "datePublished": "2022-06-03", "url": "https://questionsmedicales.fr/article/35964999", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/bs.ircmb.2022.04.013" } }, { "@type": "ScholarlyArticle", "name": "The role of dendritic cells in the immune niche of the peritoneum.", "datePublished": "2022-06-21", "url": "https://questionsmedicales.fr/article/35964997", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/bs.ircmb.2022.04.012" } }, { "@type": "ScholarlyArticle", "name": "Closure of pelvic peritoneum with bladder peritoneum flap reconstruction after laparoscopic extralevator abdominoperineal excision: A prospective stage II study.", "datePublished": "2023-07-18", "url": "https://questionsmedicales.fr/article/37462103", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jso.27382" } }, { "@type": "ScholarlyArticle", "name": "Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.", "datePublished": "2022-08-13", "url": "https://questionsmedicales.fr/article/35962920", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11912-022-01315-y" } }, { "@type": "ScholarlyArticle", "name": "Malignant mesothelioma of the peritoneum mimicking primary peritonitis carcinomatosis.", "datePublished": "2022-11-23", "url": "https://questionsmedicales.fr/article/36416471", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/01443615.2022.2141616" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Mécanismes moléculaires de l'action pharmacologique", "item": "https://questionsmedicales.fr/mesh/D045504" }, { "@type": "ListItem", "position": 5, "name": "Antienzymes", "item": "https://questionsmedicales.fr/mesh/D004791" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Antienzymes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Antienzymes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Antienzymes", "description": "Comment diagnostiquer une inhibition enzymatique ?\nQuels symptômes indiquent une inhibition enzymatique ?\nQuels tests sont utilisés pour détecter les antienzymes ?\nPeut-on utiliser l'imagerie pour diagnostiquer ?\nQuels marqueurs biochimiques sont associés aux antienzymes ?", "url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Peritoneum#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Antienzymes", "description": "Quels sont les symptômes d'une inhibition enzymatique ?\nL'inhibition enzymatique peut-elle causer des douleurs ?\nY a-t-il des symptômes spécifiques selon l'enzyme inhibée ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Peritoneum#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Antienzymes", "description": "Comment prévenir l'inhibition enzymatique ?\nLes vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?\nY a-t-il des habitudes de vie à adopter ?\nLes contrôles médicaux réguliers sont-ils importants ?\nL'éducation sur les médicaments est-elle nécessaire ?", "url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Peritoneum#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Antienzymes", "description": "Quels traitements existent pour l'inhibition enzymatique ?\nLes antienzymes sont-ils utilisés en chimiothérapie ?\nComment les inhibiteurs enzymatiques sont-ils administrés ?\nY a-t-il des effets secondaires aux antienzymes ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Peritoneum#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Antienzymes", "description": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?\nL'inhibition enzymatique peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques de surdosage avec les antienzymes ?\nComment gérer les complications liées aux antienzymes ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Peritoneum#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Antienzymes", "description": "Quels sont les facteurs de risque d'inhibition enzymatique ?\nL'âge influence-t-il le risque d'inhibition enzymatique ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe mode de vie affecte-t-il le risque ?\nLes médicaments peuvent-ils être des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Peritoneum#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une inhibition enzymatique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses biochimiques évaluent l'activité enzymatique." } }, { "@type": "Question", "name": "Quels symptômes indiquent une inhibition enzymatique ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, la douleur abdominale ou des troubles digestifs peuvent apparaître." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les antienzymes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les tests d'activité enzymatique et les dosages spécifiques d'anticorps sont courants." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour diagnostiquer ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à évaluer les organes affectés, mais n'est pas spécifique aux antienzymes." } }, { "@type": "Question", "name": "Quels marqueurs biochimiques sont associés aux antienzymes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux d'enzymes spécifiques dans le sang peuvent indiquer une inhibition enzymatique." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une inhibition enzymatique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleurs abdominales, nausées, et troubles métaboliques." } }, { "@type": "Question", "name": "L'inhibition enzymatique peut-elle causer des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des douleurs dues à des troubles digestifs ou métaboliques." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques selon l'enzyme inhibée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes varient selon l'enzyme affectée, comme la lactase ou la lipase." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent être asymptomatiques malgré une inhibition enzymatique." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver si l'inhibition persiste sans traitement approprié." } }, { "@type": "Question", "name": "Comment prévenir l'inhibition enzymatique ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et l'évitement de substances toxiques peuvent aider." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent prévenir des infections qui causent des inhibitions enzymatiques." } }, { "@type": "Question", "name": "Y a-t-il des habitudes de vie à adopter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, éviter l'alcool et le tabac peut réduire le risque d'inhibition enzymatique." } }, { "@type": "Question", "name": "Les contrôles médicaux réguliers sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes enzymatiques." } }, { "@type": "Question", "name": "L'éducation sur les médicaments est-elle nécessaire ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comprendre les effets des médicaments aide à prévenir les inhibitions enzymatiques." } }, { "@type": "Question", "name": "Quels traitements existent pour l'inhibition enzymatique ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments spécifiques et des modifications diététiques." } }, { "@type": "Question", "name": "Les antienzymes sont-ils utilisés en chimiothérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains antienzymes sont utilisés pour cibler des enzymes dans les cellules cancéreuses." } }, { "@type": "Question", "name": "Comment les inhibiteurs enzymatiques sont-ils administrés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être administrés par voie orale, intraveineuse ou topique selon le cas." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux antienzymes ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des nausées, des éruptions cutanées ou des douleurs peuvent survenir." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le traitement est souvent adapté en fonction de la cause et de la gravité de l'inhibition." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des troubles métaboliques ou des maladies organiques peuvent survenir." } }, { "@type": "Question", "name": "L'inhibition enzymatique peut-elle entraîner des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une inhibition prolongée peut contribuer à des maladies chroniques comme le diabète." } }, { "@type": "Question", "name": "Y a-t-il des risques de surdosage avec les antienzymes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un surdosage peut entraîner des effets indésirables graves et des complications." } }, { "@type": "Question", "name": "Comment gérer les complications liées aux antienzymes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi médical régulier et des ajustements de traitement." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié et rapide." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'inhibition enzymatique ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des maladies héréditaires et des habitudes alimentaires." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'inhibition enzymatique ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente souvent avec l'âge en raison de la dégradation enzymatique naturelle." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque d'inhibition enzymatique." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils être des facteurs de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent interférer avec l'activité enzymatique et augmenter le risque." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale

Validation scientifique effectuée le 22/04/2025

Contenu vérifié selon les dernières recommandations médicales

En savoir plus sur Dr Menir

Sous-catégories

48 au total
└─

Inhibiteurs des protéines activatrices de la 5-lipoxygénase

5-Lipoxygenase-Activating Protein Inhibitors D058946 - D27.505.519.389.086
└─

Inhibiteurs de l'acétaldéhyde déshydrogénase

Acetaldehyde Dehydrogenase Inhibitors D065086 - D27.505.519.389.089
└─

Inhibiteurs de l'adénosine désaminase

Adenosine Deaminase Inhibitors D058892 - D27.505.519.389.092
└─

Inhibiteurs des adénylate cyclases

Adenylyl Cyclase Inhibitors D000067956 - D27.505.519.389.108
└─

Inhibiteurs de la calcineurine

Calcineurin Inhibitors D065095 - D27.505.519.389.174
└─

Inhibiteurs de l'anhydrase carbonique

Carbonic Anhydrase Inhibitors D002257 - D27.505.519.389.200
└─

Inhibiteurs et modulateurs de la gamma-secrétase

Gamma Secretase Inhibitors and Modulators D000091062 - D27.505.519.389.315
└─

Inhibiteurs des enzymes du cytochrome P-450

Cytochrome P-450 Enzyme Inhibitors D065607 - D27.505.519.389.335
└─

Antifoliques

Folic Acid Antagonists D005493 - D27.505.519.389.350
└─

Inhibiteurs de désacétylase d'histone

Histone Deacetylase Inhibitors D056572 - D27.505.519.389.360
└─

Inhibiteurs de l'intégrase

Integrase Inhibitors D019429 - D27.505.519.389.375
└─

Inhibiteurs de la lipoxygénase

Lipoxygenase Inhibitors D016859 - D27.505.519.389.480
└─

Inhibiteurs de la monoamine oxydase

Monoamine Oxidase Inhibitors D008996 - D27.505.519.389.616
└─

Inhibiteurs de la synthèse d'acide nucléique

Nucleic Acid Synthesis Inhibitors D019384 - D27.505.519.389.675
└─

Inhibiteurs de l'ornithine décarboxylase

Ornithine Decarboxylase Inhibitors D065108 - D27.505.519.389.705
└─

Inhibiteurs de la phosphodiestérase

Phosphodiesterase Inhibitors D010726 - D27.505.519.389.735
└─

Inhibiteurs des phosphoinositide-3 kinases

Phosphoinositide-3 Kinase Inhibitors D000081082 - D27.505.519.389.736
└─

Inhibiteurs de la phospholipase A2

Phospholipase A2 Inhibitors D064801 - D27.505.519.389.737
└─

Inhibiteurs de prolyle hydroxylases

Prolyl-Hydroxylase Inhibitors D064800 - D27.505.519.389.740
└─

Inhibiteurs de protéases

Protease Inhibitors D011480 - D27.505.519.389.745
└─

Inhibiteurs de protéines kinases

Protein Kinase Inhibitors D047428 - D27.505.519.389.755
└─

Inhibiteurs de la synthèse protéique

Protein Synthesis Inhibitors D011500 - D27.505.519.389.760
└─

Inhibiteurs de la pompe à protons

Proton Pump Inhibitors D054328 - D27.505.519.389.848
└─

Agents découplants

Uncoupling Agents D014475 - D27.505.519.389.936
└─└─

Inhibiteurs du cytochrome P-450 CYP1A2

Cytochrome P-450 CYP1A2 Inhibitors D065609 - D27.505.519.389.335.120
└─└─

Inhibiteurs du cytochrome P-450 CYP2B6

Cytochrome P-450 CYP2B6 Inhibitors D065686 - D27.505.519.389.335.260
└─└─

Inhibiteurs du cytochrome P-450 CYP2C8

Cytochrome P-450 CYP2C8 Inhibitors D065687 - D27.505.519.389.335.308
└─└─

Inhibiteurs du cytochrome P-450 CYP2C19

Cytochrome P-450 CYP2C19 Inhibitors D065689 - D27.505.519.389.335.319
└─└─

Inhibiteurs du cytochrome P-450 CYP2C9

Cytochrome P-450 CYP2C9 Inhibitors D065688 - D27.505.519.389.335.329
└─└─

Inhibiteurs du cytochrome P-450 CYP2D6

Cytochrome P-450 CYP2D6 Inhibitors D065690 - D27.505.519.389.335.368
└─└─

Inhibiteurs du cytochrome P-450 CYP2E1

Cytochrome P-450 CYP2E1 Inhibitors D065691 - D27.505.519.389.335.421
└─└─

Inhibiteurs du cytochrome P-450 CYP3A

Cytochrome P-450 CYP3A Inhibitors D065692 - D27.505.519.389.335.503
└─└─

Inhibiteurs de la phosphodiestérase-3

Phosphodiesterase 3 Inhibitors D058987 - D27.505.519.389.735.249
└─└─

Inhibiteurs de la phosphodiestérase-4

Phosphodiesterase 4 Inhibitors D058988 - D27.505.519.389.735.374
└─└─

Inhibiteurs de la phosphodiestérase-5

Phosphodiesterase 5 Inhibitors D058986 - D27.505.519.389.735.500
└─└─

Inhibiteurs de l'enzyme de conversion de l'angiotensine

Angiotensin-Converting Enzyme Inhibitors D000806 - D27.505.519.389.745.085
└─└─

Inhibiteurs de la cystéine protéinase

Cysteine Proteinase Inhibitors D015853 - D27.505.519.389.745.325
└─└─

Inhibiteurs de métalloprotéinases matricielles

Matrix Metalloproteinase Inhibitors D061965 - D27.505.519.389.745.610
└─└─

Inhibiteurs du protéasome

Proteasome Inhibitors D061988 - D27.505.519.389.745.705
└─└─

Inhibiteurs de la rénine

Renin Inhibitors D000092502 - D27.505.519.389.745.753
└─└─

Inhibiteurs de la sérine protéinase

Serine Proteinase Inhibitors D015842 - D27.505.519.389.745.800
└─└─

Inhibiteurs des Janus kinases

Janus Kinase Inhibitors D000075242 - D27.505.519.389.755.500
└─└─

Inhibiteurs de protéine-tyrosine kinase

Tyrosine Protein Kinase Inhibitors D000092004 - D27.505.519.389.755.875
└─└─└─

Inhibiteurs des vasopeptidases

Vasopeptidase Inhibitors D000075563 - D27.505.519.389.745.085.500
└─└─└─

Inhibiteurs des caspases

Caspase Inhibitors D061945 - D27.505.519.389.745.325.500
└─└─└─

Inhibiteurs de serine peptidase de type Kazal

Serine Peptidase Inhibitors, Kazal Type D000074162 - D27.505.519.389.745.800.562
└─└─└─

Serpines

Serpins D015843 - D27.505.519.389.745.800.675
└─└─└─

Inhibiteurs trypsiques

Trypsin Inhibitors D014361 - D27.505.519.389.745.800.900

Auteurs principaux

Xiaoxi Liu

2 publications dans cette catégorie

Affiliations :
  • Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :

Robert S Magin

2 publications dans cette catégorie

Affiliations :
  • Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :

Nathan J Schauer

2 publications dans cette catégorie

Affiliations :
  • Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :

Sara J Buhrlage

2 publications dans cette catégorie

Affiliations :
  • Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
  • Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
  • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Publications dans "Antienzymes" :

R Gentry Wilkerson

2 publications dans cette catégorie

Affiliations :
  • Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: gwilkerson@som.umaryland.edu.
Publications dans "Antienzymes" :

Michael E Winters

2 publications dans cette catégorie

Affiliations :
  • Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: https://twitter.com/critcareguys.
Publications dans "Antienzymes" :

Frédéric Rodriguez

2 publications dans cette catégorie

Affiliations :
  • Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR5068, CNRS, Université Paul Sabatier Toulouse III, 31062 Toulouse, France.
Publications dans "Antienzymes" :

Giulia Degiacomi

2 publications dans cette catégorie

Affiliations :
  • Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Publications dans "Antienzymes" :

Maria Rosalia Pasca

2 publications dans cette catégorie

Affiliations :
  • Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Publications dans "Antienzymes" :

Christian Lherbet

2 publications dans cette catégorie

Affiliations :
  • Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR5068, CNRS, Université Paul Sabatier Toulouse III, 31062 Toulouse, France.
Publications dans "Antienzymes" :

Ekaterina Knyazhanskaya

1 publication dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States.
Publications dans "Antienzymes" :

Marc C Morais

1 publication dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States.
Publications dans "Antienzymes" :

Kyung H Choi

1 publication dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States. Electronic address: kychoi@utmb.edu.
Publications dans "Antienzymes" :

Yaling Huang

1 publication dans cette catégorie

Affiliations :
  • Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :

Jian Jiang

1 publication dans cette catégorie

Affiliations :
  • Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :

Yanqiu Wang

1 publication dans cette catégorie

Affiliations :
  • Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :

Jie Chen

1 publication dans cette catégorie

Affiliations :
  • Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :

Juqun Xi

1 publication dans cette catégorie

Affiliations :
  • Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
  • Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :

Athina Geronikaki

1 publication dans cette catégorie

Affiliations :
  • School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Publications dans "Antienzymes" :

Phaedra T Eleutheriou

1 publication dans cette catégorie

Affiliations :
  • Clinical Chemistry-Biochemistry, International Hellenic University, 57400 Thessalonik, Greece.
Publications dans "Antienzymes" :

Sources (264 au total)

Closure of pelvic peritoneum with bladder peritoneum flap reconstruction after laparoscopic extralevator abdominoperineal excision: A prospective stage II study.

Oct 2023
DOI: 10.1002/jso.27382 PMID: 37462103

Extralevator abdominoperineal resection (ELAPE) has increased perineal wound complications due to the extended resection area. Closure of the pelvic peritoneum (CPP) may exclude the abdominal content ... This is a prospective single-arm study at the development and exploration phase and fulfills the IDEAL framework stage II. Ultralow rectal cancer patients with rigid pelvis who underwent ELAPE with BL... Among 27 patients included, the overall success rate of BLAPER was 96.3% (26/27). Indocyanine green fluorescence imaging and antiadhesive barrier placement were introduced to improve the BLAPER techni... BLAPER is safe and may prevent the small bowel from descending into the retrourogenital space and subsequently developing PH and SBO without increasing the intraoperative and postoperative complicatio...

Humans Peritoneum Urinary Bladder Prospective Studies Laparoscopy +5 autres

Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.

11 2022
DOI: 10.1007/s11912-022-01315-y PMID: 35962920

Low-grade serous ovarian cancer (LGSOC) is a rare form of epithelial ovarian cancer that generally exhibits a protracted course and is less sensitive to chemotherapy than high-grade serous ovarian can... Endocrine therapy is frequently used for the treatment of patients with recurrent LGSOC and is now also part of the standard upfront treatment of this disease, with an ongoing phase III clinical trial...

Female Humans Carcinoma, Ovarian Epithelial Peritoneum Cystadenocarcinoma, Serous +3 autres

HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum.

Apr 2023
DOI: 10.1007/s12094-022-03004-5 PMID: 36401054

Peritoneal metastases (PM) have a poor prognosis in gastric cancer (GC). Cytoreductive surgery (CRS) gives favorable outcomes, but the influence of hyperthermic intraperitoneal chemotherapy (HIPEC) re... PubMed, Scopus, Embase and Cochrane library accessed to collect data and language is restricted to English. RevMan 5.4 was used to perform statistical analysis. The outcomes for categorical variables ... Ten trials involving 1367 patients in which 707 were CRS-HIPEC, while 660 CRS. We got significant results in 3rd year survival (P < 0.05), while 1st and 5th years are not statistically significant P >... To compare with CRS, CRS-HIPEC has improved survival rate in deprived of further morbidity or mortality....

Humans Peritoneum Stomach Neoplasms Hyperthermic Intraperitoneal Chemotherapy Peritoneal Neoplasms +5 autres

Surgical efficacy and quality of wide resection of the pelvic peritoneum in patients with epithelial ovarian cancer.

Jun 2023
DOI: 10.1016/j.suronc.2023.101946 PMID: 37094499

The aim of the study was to evaluate the impact of adding an extensive pelvic peritoneal stripping procedure, termed "wide resection of the pelvic peritoneum," (WRPP) to standard surgery for epithelia... A total of 166 patients with ovarian cancer undergoing surgical treatment at Kumamoto University Hospital between 2002 and 2018 were retrospectively analyzed. Eligible patients were divided into three... With respect to patients with stage IIIA-IVB ovarian cancer, there were significant differences in overall and progression-free survival between the WRPP and SS groups, as revealed by univariate (haza... The present study demonstrates that WRPP significantly contributes to improved survival in patients with stage IIIA-IVB ovarian cancer. WRPP could result in eradicating ovarian CSCs and disrupting the...

Humans Female Carcinoma, Ovarian Epithelial Peritoneum Epithelial Cell Adhesion Molecule +4 autres

Spontaneous regression of migrated ventriculoperitoneal shunt catheter from scrotum to peritoneum: a case-based review.

Jan 2024
DOI: 10.1007/s00381-023-06192-9 PMID: 37857859

The incidence of scrotal migration of a ventriculoperitoneal shunt (VPS) catheter is rare and may lead to life-threatening visceral complications. Management requires prompt removal of the migrated po... A systematic search of publications in the English language is performed in PubMed and Google Scholar. Our findings show that there are 49 reported cases (including our patient) of scrotal migration o... Scrotal migration of a VPS catheter is a rare but potentially life-threatening complication in children. Our case report highlights the role of updated preoperative imaging and the need for consistent...

Male Child Humans Adolescent Scrotum +6 autres